A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)

312 participants · First posted Aug 10, 2026

A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)

478 participants · First posted Jun 22, 2012

A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)

92 participants · First posted Apr 11, 2024

ALKS-2680

ALKS-1140

ALKS-6610

Alkermes plc

Ireland

ALK-ABELLO, INC.

United States

ALK-ABELLO A/S

Denmark

Alkermes' orexin 2 receptor agonist ALKS 7290 shows symptom reductions in Phase 1b ADHD trial

Alkermes Presents Positive Phase 1b Data for ALKS 2680 in Narcolepsy Type 2 and Idiopathic Hypersomnia

FDA Panel Approves Sage's Novel Antidepressant for Postnatal Depression, Rejects Alkermes' Treatment